Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
14 October 2016
|
| In: |
EMBO molecular medicine
Year: 2016, Volume: 8, Issue: 11, Pages: 1265-1288 |
| ISSN: | 1757-4684 |
| DOI: | 10.15252/emmm.201505889 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.15252/emmm.201505889 Verlag, lizenzpflichtig, Volltext: https://www.embopress.org/doi/abs/10.15252/emmm.201505889 
|
| Author Notes: | Jörg T. Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A. Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G. Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J. Koss, Christian Klein, David T. Shima & Guido Hartmann |
| Summary: | The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. |
|---|---|
| Item Description: | Gesehen am 19.02.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1757-4684 |
| DOI: | 10.15252/emmm.201505889 |